GlassScriptPhysician profile
Stacy P Smith
NPI 1316930886
$49,041.35
in general payments reported to CMS, 2019-2025
59 companies · $3,101 in 2025
The $3,101 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14K · 2022: $21K · 2023: $5,864 · 2024: $5,035 · 2025: $3,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,981 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,981 · Travel and Lodging: $37.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,981.02 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,981.25 |
| Travel and Lodging | $37.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19,863.66 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $7,055.81 | 2021-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $5,405.04 | 2021-2025 | Ultomiris, Soliris |
| Biogen, INC. | $2,494.80 | 2021-2025 | Tysabri, Vumerity, Plegridy |
| Eli Lilly and Company | $2,053.19 | 2022-2023 | |
| Emd Serono, INC. | $1,448.35 | 2021-2025 | Mavenclad, Mavenclad |
| Allergan, INC. | $1,266.87 | 2021 | |
| Argenx US, INC. | $1,142.33 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Horizon Therapeutics Plc | $756.30 | 2021-2023 | Uplizna |
| Novartis Pharmaceuticals Corporation | $671.39 | 2021-2025 | |
| Lilly USA, LLC | $602.80 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Pfizer INC. | $531.35 | 2021-2025 | |
| Genzyme Corporation | $430.86 | 2021-2025 | |
| Tg Therapeutics, INC. | $415.04 | 2023-2025 | |
| Eisai INC. | $391.80 | 2023-2025 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $351.88 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Celgene Corporation | $302.16 | 2021-2024 | Zeposia |
| Amneal Pharmaceuticals LLC | $280.87 | 2021-2025 | Crexont, Rytary |
| Ucb, INC. | $265.81 | 2023-2025 | Zilbrysq, Briviact, Nayzilam |
| Genentech USA, INC. | $255.61 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Sunovion Pharmaceuticals INC. | $231.62 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $231.10 | 2023-2025 | Hyqvia |
| Mdd US Operations, LLC | $226.77 | 2022-2024 | Apokyn, Apokyn |
| Lundbeck LLC | $207.26 | 2021-2025 | Vyepti, Rexulti |
| Csl Behring | $205.32 | 2022-2025 | Hizentra |
| Otsuka America Pharmaceutical, INC. | $178.56 | 2023-2025 | Rexulti, Nuedexta |
| Merz Pharmaceuticals, LLC | $163.84 | 2023-2025 | Xeomin, Inbrija |
| Amgen INC. | $156.15 | 2021-2025 | Uplizna |
| Ani Pharmaceuticals, INC. | $138.09 | 2022-2025 | Purified Cortrophin Gel |
| Janssen Pharmaceuticals, INC | $115.16 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $112.24 | 2023 | Aptiom |
| Tanabe Pharma America, INC. | $101.29 | 2021-2025 | Radicava |
| Biohaven Pharmaceuticals, INC. | $100.69 | 2021 | |
| Upsher-Smith Laboratories LLC | $95.24 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $89.84 | 2022 | |
| Sk Life Science, INC. | $75.71 | 2021-2024 | |
| Kyowa Kirin, INC. | $71.52 | 2022-2023 | Nourianz |
| C2n Diagnostics, LLC | $43.59 | 2025 | Precivityad2 |
| Alnylam Pharmaceuticals INC. | $40.52 | 2023 | Onpattro |
| Corium, LLC | $40.38 | 2022-2023 | Adlarity |
| Grifols USA, LLC | $40.34 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $38.78 | 2021-2023 | |
| Acorda Therapeutics, INC | $38.54 | 2021 | |
| Avanir Pharmaceuticals, INC. | $34.78 | 2021 | |
| Almatica Pharma LLC | $26.67 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.96 | 2023 | Keveyis |
| Neurelis, INC. | $24.61 | 2025 | Valtoco |
| Axsome Therapeutics, INC. | $23.58 | 2024 | Sunosi |
| Boston Scientific Corporation | $22.14 | 2022 | |
| Cycle Pharmaceuticals INC | $20.32 | 2025 | Bafiertam, Tascenso Odt |
| Banner Life Sciences, LLC | $19.83 | 2021 | |
| Adamas Pharmaceuticals, INC. | $19.64 | 2021 | |
| Acadia Pharmaceuticals INC | $16.79 | 2021 | |
| Bio Products Laboratory USA, INC. | $14.76 | 2023 | Coagadex, Gammaplex |
| Insightec,INC | $14.58 | 2023 | Exablate |
| Nevro Corp. | $13.75 | 2022 | |
| Avion Pharmaceuticals | $13.43 | 2022 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Aucta Pharmaceuticals, INC. | $10.88 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.